CORRECTION

Correction to: Dinutuximab beta in high-risk neuroblastoma: a profile of its use

Kate McKeage¹ · Katherine A. Lyseng-Williamson¹

Published online: 6 June 2018

© Springer International Publishing AG, part of Springer Nature 2018

Correction to: Drugs Ther Perspect

<https://doi.org/10.1007/s40267-018-0522-2>

The Acknowledgements section on the last page should read:

“The manuscript was reviewed by: *P.F. Ambros*, Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria; *F.H. Felix*, Pediatric Cancer Center, Hospital Infantil Albert Sabin, Fortaleza, Brazil; *R. Kebudi*, Division of Pediatric Hematology-Oncology, Cerrahpaşa Medical Faculty & Oncology Institute, Istanbul, Turkey; *H.B. Lindsay*, Pediatric Hematology/Oncology, Baylor College of Medicine, Houston, TX, USA; *J. Morales*, Pharmacy Department, Hospital Dr Luis Calvo Mackenna, Santiago, Chile. During the peer review process, EUSA Pharma (UK) Limited, the marketing-authorisation holder of dinutuximab beta, was offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s40267-018-0522-2>.

✉ Katherine A. Lyseng-Williamson
ntp@adis.com

¹ Springer, Private Bag 65901, Mairangi Bay, 0754 Auckland, New Zealand